Conversion of antigen-specific effector/memory T cells into Foxp3-expressing T reg cells by inhibition of CDK8/19

Author:

Akamatsu Masahiko12ORCID,Mikami Norihisa34ORCID,Ohkura Naganari35,Kawakami Ryoji3,Kitagawa Yohko3,Sugimoto Atsushi3,Hirota Keiji4,Nakamura Naoto2ORCID,Ujihara Satoru2ORCID,Kurosaki Toshio2ORCID,Hamaguchi Hisao2ORCID,Harada Hironori2ORCID,Xia Guliang6,Morita Yoshiaki12ORCID,Aramori Ichiro12,Narumiya Shuh1ORCID,Sakaguchi Shimon34ORCID

Affiliation:

1. Center for Innovation in Immunoregulation Technology and Therapeutics, Kyoto University Graduate School of Medicine, Konoe-cho Yoshida, Sakyo-ku, Kyoto, Kyoto 606-8501, Japan.

2. Drug Discovery Research, Astellas Pharma Inc., Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan.

3. Department of Experimental Immunology, WPI Immunology Frontier Research Center, Osaka University, Yamadaoka, Suita, Osaka 565-0871, Japan.

4. Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Kyoto 606-8507, Japan.

5. Department of Frontier Research in Tumor Immunology, Center of Medical Innovation and Translational Research, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.

6. Astellas Research Institute of America, Skokie, IL 60077, USA.

Abstract

CDK8/19 inhibitors can convert naïve and memory/effector T cells into T reg cells capable of treating immunological diseases.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3